-
Adalimumab, sold
under the
brand name
Humira and others, is a disease-modifying
antirheumatic drug and
monoclonal antibody used to
treat rheumatoid arthritis...
-
Based on
studies in AS, the
results suggest infliximab, etanercept, and
adalimumab have the
potential to
reduce the
signs and
symptoms of
moderate to severely...
- non-infectious
uveitis that does not
respond to
conventional immunosuppression.
Adalimumab, a
monoclonal antibody that
blocks tumor necrosis factor-alpha (TNF-α)...
-
superior to
adalimumab for ACR50, DAS28CRP≤3.2, ΔPain and ΔHAQDI. At w**** 26, more parti****nts on
upadacitinib vs
placebo or
adalimumab achieved low...
- ****ociated
intellectual property.
Biosimilars available in
Australia include adalimumab, bevacizumab, enoxaparin,
epoetin lambda, etanercept, filgrastim, follitropin...
-
Adalat adalimumab (USAN)
adalimumab-aacf
adalimumab-aaty
adalimumab-adaz
adalimumab-adbm
adalimumab-afzb
adalimumab-aqvh
adalimumab-atto
adalimumab-bwwd...
- and rank 89 on the 2024 list. The company's
primary product is
Humira (
adalimumab) ($14 billion in 2023 revenues, 27 percent of total),
administered via...
-
circulating receptor such as
infliximab (Remicade),
etanercept (Enbrel), or
adalimumab (Humira) that
binds to TNF-α,
preventing it from
inducing the synthesis...
-
effects can be
achieved with a
monoclonal antibody such as infliximab,
adalimumab,
certolizumab pegol, and golimumab, or with a
circulating receptor fusion...
- with
inflammatory bowel disease. TNF-α
Inhibitor treatments (infliximab,
adalimumab, certolizumab, natalizumab, and etanercept) are
thought to be the cause...
